ACC 2023: Late-Breaking Science Video Collection
Published: 06 March 2023
-
Views:
6153 -
Likes:
7
-
Views:
6153 -
Likes:
7
-
Up Next
-
3m 44sPart 2 | Session 7 MK-0616: Oral PCSK9 inhibitor In Hypercholesterolemia Patients
-
5m 21sPart 2 | Session 8 Evaluation of the Mechanism of Benefit for Dapagliflozin in HFpEF
-
3m 7sPart 2 | Session 9 BMAD Trial: μCor in Ambulatory Decompensated Heart Failure
-
5m 44s
-
8m 2s
-
33m 36sPart 3 | Session 1 ACC.23 Late-breaking Science Wrap Up
-
22m 4sPart 3 | Session 2 What's Hot at ACC.23? Late-breaking Science Preview
-
16m 22s
-
5m 34sPart 4 | Session 2 Lipid Management & the CLEAR Trial with Dr Erin Michos
-
17m 7sPart 4 | Session 3 Obesity Management Strategies in 2023 with Dr Harold Bays
-
15m 9sPart 4 | Session 4 ACC.23 President Interview with Dr B Hadley Wilson
-
1m 17sPart 5 | Session 1 Dr Akowuah: Cardiovascular Research & Message for Early-Career Researchers
-
1m 22sPart 5 | Session 2 Dr Kini: Asking Questions & Her Motivation to Do Research on Plaque
-
5m 29s
-
1m 21sPart 5 | Session 4 Dr Verma: Passion for Electrophysiology & His Advice For Young Researchers
-
3m 33s
-
31sPart 5 | Session 6 Dr Hahn: Innovative Areas of Cardiovascular Science in 2023
-
1m 33sPart 5 | Session 7 Dr Forrest: Structural Heart Innovations and Advice to Young Researchers
-
16m 12sPart 1 | Session 1 The CLEAR-Outcomes Trial with Dr Harriette Van Spall & Dr Steven Nissen Harriette Van Spall, Steven E Nissen
-
16m 24sPart 1 | Session 2 The REVIVED-BCIS2 Viability Study with Dr Harriette Van Spall, Dr Divaka Perera & Dr Peter O'Kane Harriette Van Spall, Divaka Perera, Peter O’Kane
-
14m 3sPart 1 | Session 3 The BETTER-CARE HF Trial with Dr Harriette Van Spall & Dr Amrita Mukhopadhyay Amrita Mukhopadhyay, Harriette Van Spall
-
17m 32sPart 1 | Session 4 The COORDINATE-Diabetes Trial with Dr Harriette Van Spall, Dr Neha J Pagidipati & Dr Christopher B Granger Christopher B Granger, Harriette Van Spall, Neha Pagidipati
-
12m 7sPart 1 | Session 5 The BIOVASC Trial with Dr Harriette Van Spall & Prof Roberto Diletti Roberto Diletti, Harriette Van Spall
-
5m 59sPart 2 | Session 1 Statins to Protect Heart During Cancer Treatment: The STOP-CA Trial Marielle Scherrer-Crosbie
-
5m 38sPart 2 | Session 2 RENOVATE-COMPLEX-PCI: IVUS Vs OCT Optimisation in Complex PCI Joo-Yong Hahn
-
8m 1sPart 2 | Session 3 Effect of Evolocumab on Coronary Plaque Morphology: The YELLOW III Study Annapoorna Kini
-
5m 41sPart 2 | Session 4 Mini-Thoracotomy Vs Sternoctomy for Degenerative Valve Disease: The UK Mini-Mitral Study Enoch Akowuah
-
3m 46sPart 2 | Session 5 TAVR in Low-Risk Aortic Stenosis Patients: 3-Year Results From the Evolut Low Risk Trial John Forrest
Overview
Our regular review series View from the Thoraxcenter, hosted by Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcentre, Erasmus MC, Rotterdam, NL) provides a critical analysis of the late-breaking and featured science results and spotlights impactful data.
For a deeper look into the key clinical trial data revealed at ACC 23, Dr Harriette Van Spall (McMaster University, Hamilton, CA) interviews the principal investigators in her regular Late-Breaker Discussion Series.
For short, concise coverage of the key data revealed, our accessible Expert Interviews were conducted with select faculty, focussing on the results, applicability and impact on future research.
More from this programme
Part 1
Late-Breaker Discussion Series
Host, Dr Harriette Van Spall is joined by principle investigators for discussion on selected late-breaking trials.
Part 2
Expert Interviews
Part 3
View from the Thoraxcenter
In these concise episodes of View from the Thoraxcenter, Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcentre, Erasmus MC, Rotterdam, NL) offer their thoughts on the top late-breaking trials that will be presented at ACC 2023.
Part 4
Highlights Reviews
Part 5
Behind the Heart
Watch our Behind the Heart series to learn more the personal perspectives from the investigators behind top trials in cardiovascular science.
About the episode
Principal Investigator, Dr Atul Verma (McGill University Health Centre, CA) joins us on-site at ACC's 2023 Scientific Sessions to outline the findings of the PULSED-AF Trial (Medtronic Cardiac Rhythm and Heart Failure). In this prospective, multicenter study, 421 patients with persistent atrial fibrillation (AF) were treated with the Medtronic PulseSelect Pulsed Field Ablation (PFA) System to study the safety and effectiveness of this device.
Questions:
1. What is the background of this trial?
2. What are benefits of this novel technology?
3. Can you tell us about the study design, eligibility criteria and outcome measures?
4. What are the findings presented at ACC?
5. What are the potential implications of this data on practice and further research?
6. What are the next steps?
Recorded on-site at ACC 2023, New Orleans.
Faculty Biographies
Atul Verma
Director of Cardiology
Dr Atul Verma is currently Director of Cardiology at the McGill University Health Centre & McGill University, Montreal, CA. He is head of the Heart Rhythm Programme at Southlake Regional Health Centre and an Associate Professor at the University of Toronto, US. He is also an Associate Scientist with the Li Ka Shing Knowledge Institute.
Specialising in complex arrhythmias like atrial fibrillation and ventricular tachycardia, he has published over 300 peer-reviewed articles including in The New England Journal of Medicine. Dr Verma has co-chaired the Canadian Cardiovascular Society Atrial Fibrillation Guidelines Committee and contributed to the HRS/EHRA Consensus Document on Catheter Ablation of Atrial Fibrillation. He currently leads and participates in multiple international clinical trials.
Comments